Metastasis-associated protein 2 (MTA2) (MTA2)

Metastasis-associated protein 2 (MTA2), also known as Metastasis tumor antigen 2, is a critical component of the nucleosome remodeling and deacetylase (NuRD) complex, which plays a central role in chromatin architecture and transcriptional regulation. It functions as a transcriptional co-repressor by recruiting histone deacetylases to specific gene promoters and by directly deacetylating non-histone proteins such as the tumor suppressor p53 and the estrogen receptor alpha. In many human cancers, including breast, lung, and gastric carcinomas, MTA2 is aberrantly overexpressed and strongly correlates with increased tumor invasion, metastasis, and poor patient prognosis. Its ability to inhibit p53-mediated apoptosis and promote epithelial-to-mesenchymal transition (EMT) makes it a significant driver of oncogenesis. While no targeted therapies are currently approved for clinical use, research into small molecule inhibitors and the repurposing of existing drugs like tramadol and nabumetone is ongoing to block its pro-metastatic activities. As a master regulator of gene expression, MTA2 represents a promising therapeutic target for preventing cancer progression and overcoming resistance to conventional treatments.

Other names

Metastasis tumor antigen 2p53-associated deacetylaseMetastasis-associated gene 1-like 1MTA1-L1

MTA2 acts as a subunit of the nucleosome remodeling and deacetylase (NuRD) complex, where it facilitates the deacetylation of both histone and non-histone proteins, such as p53 and the estrogen receptor alpha (ERα). By deacetylating p53, MTA2 inhibits p53-mediated transcriptional activation, thereby suppressing cell growth arrest and apoptosis. Drugs targeting MTA2 aim to inhibit its interaction within the NuRD complex or block its enzymatic activity to restore the function of tumor suppressors and prevent cancer metastasis.